Article
Radiology, Nuclear Medicine & Medical Imaging
Daniela-Elena Oprea-Lager, Eric Gontier, Lina Garcia-Canamaque, Mathieu Gauthe, Pierre Olivier, Mercedes Mitjavila, Pilar Tamayo, Philippe Robin, Ana Maria Garcia Vicente, Anne-Charlotte Bouyeure, Alban Bailliez, Antonio Rodriguez-Fernandez, Sinan Ben Mahmoud, Juan Antonio Vallejo-Casas, Philippe Maksud, Charles Merlin, Paul Blanc-Durand, Clement Drouet, Hubert Tissot, Irina Vierasu, Thierry Vander Borght, Evelyne Boos, Florence Chossat, Marina Hodolic, Caroline Rousseau
Summary: The purpose of this study was to compare the per-patient detection rates of [F-18]DCFPyL and [F-18]fluoromethylcholine PET/CT in patients with first prostate cancer biochemical recurrence. The results showed that [F-18]DCFPyL had a significantly higher detection rate compared to [F-18]fluoromethylcholine.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Elisa Perry, Arpit Talwar, Sanjana Sharma, Daisy O'Connor, Lih-Ming Wong, Kim Taubman, Tom R. Sutherland
Summary: This study retrospectively reviewed 1445 F-18-DCFPyL PSMA PET/CT studies and found that the detection of non-prostate cancer tumors (NPCaT) using PSMA imaging was low. In contrast, atypical prostate cancer metastases showed intermediate to high PSMA expression.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Esther Mena, Steven P. Rowe, Joanna H. Shih, Liza Lindenberg, Baris Turkbey, Aloyse Fourquet, Frank I. Lin, Stephen Adler, Philip Eclarinal, Yolanda L. McKinney, Deborah E. Citrin, William Dahut, Bradford J. Wood, Richard Chang, Elliot Levy, Maria Merino, Michael A. Gorin, Martin G. Pomper, Peter A. Pinto, Janet F. Eary, Peter L. Choyke, Kenneth J. Pienta
Summary: This study investigated the factors predicting scan positivity and disease location in patients with biochemical recurrence of prostate cancer after primary local therapy. PSA and PSAdt were found to be independent predictors of scan positivity and disease location.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ruohua Chen, Yining Wang, Yiping Shi, Yinjie Zhu, Lian Xu, Gang Huang, Jianjun Liu
Summary: Ga-68-PSMA PET/CT has a high detection rate in prostate cancer patients with biochemical recurrence, but few studies have explored other imaging methods for patients with negative Ga-68-PSMA findings. This study found that PSA level and Gleason score are independent predictors of F-18-FDG-positive findings, with patients with high PSA and Gleason score most likely to benefit from F-18-FDG PET/CT.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Keith L. Spinali, David J. Papke, Hina J. Shah
Summary: F-18-DCFPyl is used to detect recurrent or metastatic prostate cancer and can target nonprostatic disease entities that mimic prostate cancer. The interpreting physician needs to consider serum prostate-specific antigen levels and uptake distribution to avoid misdiagnosis of metastatic prostate cancer. We describe the association of F-18-DCFPyl uptake with a previously undescribed hepatic small vessel neoplasm.
CLINICAL NUCLEAR MEDICINE
(2023)
Editorial Material
Oncology
Lawrence D. True, Delphine L. Chen
Summary: Current imaging techniques for prostate cancer have limited sensitivity and specificity, but the novel PSMA agent F-18-DCFPyL-PET/CT shows promising performance.
CLINICAL CANCER RESEARCH
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Maurits Wondergem, Friso M. van der Zant, Wouter A. M. Broos, Remco J. J. Knol
Summary: This study compared the performance of F-18-DCFPyL and F-18-PSMA-1007 in clinical imaging, revealing some significant differences between the two, particularly in the ability to detect prostate lesions in patients. These findings encourage further research and may have important implications for the selection of appropriate PSMA-targeting radiopharmaceuticals.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Review
Oncology
Ke-Hao Pan, Jin-Feng Wang, Chun-Ying Wang, Abdul Aziz Nikzad, Fang Q. Kong, Li Jian, Yin-Qiu Zhang, Xiao-Ming Lu, Bin Xu, Ya-Li Wang, Ming Chen
Summary: 18F-DCFPyL PSMA PET/CT has good sensitivity and specificity for diagnosing prostate cancer, with diagnostic rate correlated with PSA levels. Further large-scale, high-quality studies are needed in the future.
FRONTIERS IN ONCOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Florian Rosar, Fadi Khreish, Robert J. Marlowe, Andrea Schaefer-Schuler, Caroline Burgard, Stephan Maus, Sven Petto, Mark Bartholomae, Samer Ezziddin
Summary: Preliminary data suggest that using Zr-89-labeled PSMA ligand radiotracers may be more effective than using tracers with short-lived radionuclides in detecting suspicious lesions in patients with biochemical recurrence of prostate cancer. In this study, 78% of patients had suspicious lesions detected on 24-h and 48-h scans, with higher detection rates on the 48-h scans. This suggests that imaging at a later time may be preferable.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Clemens Mingels, Karl Peter Bohn, Axel Rominger, Ali Afshar-Oromieh, Ian Alberts
Summary: This study investigated the diagnostic accuracy of [F-18]PSMA-1007 PET/CT in biochemically recurrent prostate cancer. The results showed good performance in terms of regional sensitivity and negative predictive value, but limited positive predictive value, especially for bone lesions.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Oncology
Yachao Liu, Hongkai Yu, Jiajin Liu, Xiaojun Zhang, Mu Lin, Holger Schmidt, Jiangping Gao, Baixuan Xu
Summary: This study demonstrated that F-18-DCFPyL PET/CT-US or PET/MRI-US fusion targeted prostate biopsies may be valuable for prostate cancer diagnosis, with a high detection rate of clinically significant prostate cancer for PET-positive lesions. PET/MR can help rule out false PET-positive lesions, potentially reducing unnecessary prostate biopsies.
FRONTIERS IN ONCOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Elisa Perry, Arpit Talwar, Kim Taubman, Michael Ng, Lih-Ming Wong, Russell Booth, Tom R. Sutherland
Summary: This retrospective multicenter analysis evaluated the performance of PSMA PET/CT with [F-18]DCFPyL in detecting and localizing recurrent prostate cancer post RP. The study found that even at low PSA levels, the detection efficacy of [F-18]DCFPyL PET/CT was high, highlighting the importance of considering patients with PSA levels < 0.5 ng/mL in guidelines and funding pathways for PSMA PET/CT.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
M. Celli, U. De Giorgi, P. Caroli, V Di Lorio, L. Fantini, V Rossetti, F. Foca, S. Nicolini, M. Giganti, G. Paganelli, F. Matteucci
Summary: This study evaluated the clinical value of (68)Ga-PSMA PET/CT negativity in patients with biochemical recurrent prostate cancer and found that ISUP subset was a significant risk factor for clinical relapse.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Florian Rosar, Mark Bartholoma, Stephan Maus, Bastiaan M. Prive, Fadi Khreish, Gerben M. Franssen, Yvonne H. W. Derks, James Nagarajah, Samer Ezziddin
Summary: In this study, Ga-68-PSMA-11 PET/CT imaging and additional Zr-89-PSMA-617 PET/CT imaging were performed on a patient, revealing a small local recurrence in the prostate bed. This highlights the potential of Zr-89-labeled PSMA ligands, such as Zr-89-PSMA-617, in identifying the source of biochemical recurrence.
CLINICAL NUCLEAR MEDICINE
(2022)
Article
Medicine, General & Internal
Florian Rosar, Caroline Burgard, Johannes Linxweiler, Mathias Wagner, Samer Ezziddin
Summary: We present an interesting image of testicular metastasis from prostate cancer using [Zr-89]Zr-PSMA-617 PET/CT imaging, in a 70-year-old man with biochemical recurrence and negative conventional [Ga-68]Ga-PSMA-11 PET/CT imaging. This case highlights the importance of considering [Zr-89]Zr-PSMA-617 PET/CT when conventional PSMA imaging fails to locate biochemical recurrence, and reminds colleagues of the rare but potential metastatic localization in this scenario.
Article
Urology & Nephrology
Dennie Meijer, Rosemarijn H. Ettema, Pim J. van Leeuwen, Theo H. van der Kwast, Henk G. van der Poel, Maarten L. Donswijk, Daniela E. Oprea-Lager, Elise M. Bekers, Andre N. Vis
Summary: This study aimed to evaluate the diagnostic ability of PSMA PET/CT for preoperative pelvic lymph node metastasis and found that suspected metastatic lymph nodes and tumor size were closely associated with postoperative biochemical progression.
Letter
Urology & Nephrology
Hilda A. de Barros, Matthias N. van Oosterom, Maarten L. Donswijk, Jeroen J. M. A. Hendrikx, Andre N. Vis, Tobias Maurer, Fijs W. B. van Leeuwen, Henk G. van der Poel, Pim J. van Leeuwen
Letter
Urology & Nephrology
Xiangyang Yao, Chen Duan, Bo Li, Xiaoliang Wu, Hua Xu
Letter
Urology & Nephrology
Hilda A. de Barros, Anne-Claire Berrens, Maarten L. Donswijk, Esther M. K. Wit, Fijs W. B. van Leeuwen, Pim J. van Leeuwen, Henk G. van der Poel
JOURNAL OF UROLOGY
(2023)
Article
Oncology
Sarah M. H. Einerhand, Charlotte S. Voskuilen, Elies E. Fransen van de Putte, Maarten L. Donswijk, Annemarie Bruining, Michiel S. van Der Heijden, Laura S. Mertens, Kees Hendricksen, Erik Vegt, Bas W. G. van Rhijn
Summary: This study investigated the differences in predicting the response of patients with muscle-invasive bladder carcinoma to neoadjuvant chemotherapy using FDG-PET/CT and CECT. The results showed that FDG-PET/CT had low accuracy and specificity in predicting complete pathological response.
Article
Radiology, Nuclear Medicine & Medical Imaging
Esther M. K. Wit, Gijs H. KleinJan, Anne-Claire Berrens, Roos van Vliet, Pim J. van Leeuwen, Tessa Buckle, Maarten L. Donswijk, Elise M. Bekers, Fijs W. B. van Leeuwen, Henk G. van der Poel
Summary: This study compared the diagnostic accuracy of the hybrid tracer ICG-Technetium-99m(Tc-99m)-nanocolloid with sequential tracers of Tc-99m-nanocolloid and free-ICG in detecting tumor-positive lymph nodes in prostate cancer patients. The results showed that the hybrid tracer approach improved the positive predictive value for tumor-bearing lymph nodes while minimizing the number of fluorescent nodes.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Manon T. A. Vreeburg, Samaneh Azargoshasb, Danny van Willigen, Tom Molenaar, Matthias N. van Oosterom, Tessa Buckle, Leon J. Slof, Martin Klop, Baris Karakullukcu, Maarten Donswijk, Henk G. van der Poel, Fijs W. B. van Leeuwen, Oscar R. Brouwer, Daphne D. D. Rietbergen
Summary: This study compared the performance of different fluorescent tracers, ICG-Tc-99m-nanocolloid and ICG-Tc-99m-nanoscan, in lymph node detection and found that they have similar effects in lymph node uptake and tumor identification. This means that ICG-Tc-99m-nanoscan can be safely used for lymph node detection.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Oncology
Sarah Rosanne Ottenhof, Hielke Martijn de Vries, Barry Doodeman, Gerbert Lambertus Vrijenhoek, Vincent van der Noort, Maarten Lucas Donswijk, Jeantine Martina de Feijter, Eva Eline Schaake, Simon Horenblas, Oscar Roberto Brouwer, Michiel Simon Heijden, Floris Jop Pos
Summary: This study aimed to evaluate the safety and efficacy of chemoradiotherapy as the primary treatment for locoregionally advanced penile carcinoma (LAPSCC) and the association of high-risk human papillomavirus (hrHPV) with the outcome. The results showed that chemoradiotherapy is a viable treatment option for LAPSCC with acceptable toxicity and can result in an enduring response. Furthermore, the study found no significant difference in outcomes between patients with hrHPV-positive and -negative tumors.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Biochemistry & Molecular Biology
Hans Veerman, Sophia H. van der Graaf, Dennie Meijer, Marinus J. Hagens, Corinne N. Tillier, Pim J. van Leeuwen, Henk G. van der Poel, Andre N. Vis
Summary: The current follow-up scheme of PSA testing after RARP is strict and burdensome to the healthcare system. However, it is found that patients with an unmeasurable PSA level at 3-4 months after surgery have a very low risk of biochemical recurrence at 5-8 months of follow-up.
Review
Oncology
Hilda A. de Barros, Isabeau van Beurden, Matteo Droghetti, Erica A. Wilthagen, Oktay Ozman, Andries M. Bergman, Shafak Aluwini, R. Jeroen A. van Moorselaar, Maarten L. Donswijk, Pim J. van Leeuwen, Henk G. van der Poel
Summary: This systematic review analyzed the literature on the oncological outcomes of hormone-sensitive prostate cancer (PCa) patients with metastasis to nonregional lymph nodes (M1a) treated with prostate-directed therapy (PDT) and/or metastasis-directed therapy (MDT). The results showed that PDT improved oncological outcomes in de novo M1a PCa patients compared to no PDT. MDT delayed the need for systemic treatment in recurrent M1a PCa patients, but further high-level evidence is needed.
EUROPEAN UROLOGY ONCOLOGY
(2023)
Article
Urology & Nephrology
Bart Geboers, Dennie Meijer, William Counter, Alexandar Blazevski, James Thompson, Paul Doan, William Gondoputro, Athos Katelaris, Anne-Maree Haynes, Warick Delprado, Gordon O'Neill, Carlo Yuen, Andre N. Vis, Pim J. van Leeuwen, Bao Ho, Victor Liu, Jonathan Lee, Maarten L. Donswijk, Daniela Oprea-Lager, Matthijs J. Scheltema, Louise Emmett, Phillip D. Stricker
Summary: This study evaluated the additional value of prostate-specific membrane antigen positron emission tomography (PSMA-PET) compared to conventional diagnostic tools for selecting patients for hemi-ablative focal therapy (FT). The results showed that by combining PSMA-PET with multiparametric magnetic resonance imaging (mpMRI) and systematic biopsies, the accuracy of selecting potential candidates for hemi-ablative FT was significantly improved.
Article
Medicine, General & Internal
Katelijne C. C. de Bie, Hans Veerman, Yves J. L. Bodar, Dennie Meijer, Pim J. van Leeuwen, Henk G. van der Poel, Maarten L. Donswijk, Andre N. Vis, Daniela E. Oprea-Lager
Summary: This study investigated the association between the expression of Ga-68- or F-18-radiolabeled prostate-specific membrane antigen (PSMA) tracer and biochemical recurrence (BCR) in primary prostate cancer (PCa) patients prior to robot-assisted radical prostatectomy (RARP). The study found that SUVmax was an independent predictor for BCR in [Ga-68]Ga-PSMA-11 and [F-18]DCFPyL-120 PET/CT scans.
Review
Urology & Nephrology
Anne-Claire Berrens, Sophie Knipper, Giancarlo Marra, Pim J. van Leeuwen, Stevie Van der Mierden, Maarten L. Donswijk, Tobias Maurer, Fijs W. B. van Leeuwen, Henk G. Van der Poel
Summary: PSMA-targeted surgery helps identify and remove malignant tissue in prostate cancer patients while preserving adjacent structures. Most studies on PSMA-targeted surgery are pilot studies with short follow-up periods.
EUROPEAN UROLOGY OPEN SCIENCE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Maarten L. Donswijk, Marceline W. Piek, Zing Cheung, Maurits Wondergem, Marcel P. M. Stokkel, Jan Paul de Boer, Iris M. C. van der Ploeg
Summary: The objective of this study was to investigate the incidences of prostate-specific membrane antigen (PSMA) thyroid incidentaloma (PTI) using different methods to define PTI, to compare the incidence of PTI among different PSMA PET tracers, and to evaluate the clinical consequences of PTI. The results showed that the incidence of PTI varies greatly among different PSMA PET tracers and is strongly dependent on the analysis method applied.
EUROPEAN RADIOLOGY
(2023)
